Genome-Wide Association Studies Market Report 2025

The genome-wide association studies market size has grown rapidly in recent years. It will grow from $1.99 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be linked to rising prevalence of chronic diseases, increasing awareness of genetic influences on disease, greater adoption of genomic research, growing government funding for genomics, and expansion of biobanks and genomic databases.

The genome-wide association studies market size is expected to see rapid growth in the next few years. It will grow to $3.76 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be linked to increased use of pharmacogenomics in clinical practice, wider adoption of multi-omics approaches, growing demand for personalized medicine, expansion of genomic research in diverse populations, and development of point-of-care genetic testing. Key trends during the forecast period include advancements in sequencing technologies, innovations in data analysis algorithms, progress in functional genomics, research on gene-environment interactions, and developments in genome editing technologies.

The growing demand for personalized medicine is expected to drive the expansion of the genome-wide association studies (GWAS) market. Personalized medicine tailors treatment and prevention strategies based on an individual’s unique genetic profile, lifestyle, and environment. This shift towards personalized medicine is fueled by advancements in genomics, which allow for the precise identification of genetic variations and the development of treatments tailored to individual needs. GWAS plays a critical role in personalized medicine by pinpointing genetic variations linked to diseases, facilitating targeted treatment strategies. These studies improve healthcare outcomes by offering insights into individual risk factors and enabling precision therapies. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 26 new personalized medicines in 2023, up from 12 in 2022. As a result, the rising demand for personalized medicine is boosting the growth of the genome-wide association studies (GWAS) market.

Key players in the genome-wide association studies (GWAS) market are focusing on innovative solutions, such as advanced research platforms, to speed up disease discovery and enhance personalized medicine applications. An advanced research platform combines a suite of tools and technologies to enable large-scale genomic data generation, analysis, and interpretation for GWAS. For instance, in January 2025, 23andMe Holding Co., a US-based biotechnology firm, launched Discover23, a platform for genetic insights and ancestry exploration. This platform allows biopharma partners to access comprehensive genetic data in a secure environment powered by Lifebit. It provides analysis-ready GWAS on over 1,000 disease cohorts based on billions of phenotypic data points from millions of participants. The platform aims to accelerate drug discovery by helping researchers uncover new disease biology, identify potential drug targets, and improve clinical trial success while safeguarding participant privacy.

In May 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired 23andMe Holding Co. for $256 million. This acquisition allows Regeneron to leverage one of the largest consumer genetic databases to enhance genomics-driven drug discovery, improve precision medicine, and advance healthcare through large-scale genetic research. The company also emphasized its commitment to maintaining high standards of data privacy and ethical conduct. 23andMe Holding Co. is a biotechnology firm offering services related to genome-wide association studies.

Major players in the genome-wide association studies market are F. Hoffmann-La Roche AG, AstraZeneca plc, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Eurofins Scientific SE, Laboratory Corporation of America Holdings, Daiichi Sankyo Company Limited, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Databricks Inc., Broad Institute of MIT and Harvard, BGI Genomics Co. Ltd., deCODE genetics Inc., Genomics England Ltd., CD Genomics Inc., Veritas Genetics Inc., Finngen, and The Wellcome Sanger Institute.

North America was the largest region in the genome-wide association studies market in 2024. The regions covered in genome-wide association studies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the genome-wide association studies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Genome-wide association studies (GWAS) are research studies that examine the entire genome of many individuals to identify genetic variations linked to specific diseases or traits. They help reveal genetic factors contributing to complex diseases or traits, supporting risk prediction, understanding disease mechanisms, and guiding the development of targeted therapies.

The primary product types of genome-wide association studies include genotyping services, genotyping kits and reagents, software and data analysis tools, and others. Genotyping services are laboratory-based services that analyze DNA to detect genetic variations for research, diagnostics, and personalized medicine. Applications include drug discovery, disease risk assessment, personalized medicine, and more, serving pharmaceutical and biotechnology companies, academic and research institutions, hospitals and clinics, and other end users.

The genome-wide association studies market research report is one of a series of new reports that provides genome-wide association studies market statistics, including genome-wide association studies industry global market size, regional shares, competitors with a genome-wide association studies market share, detailed genome-wide association studies market segments, market trends and opportunities, and any further data you may need to thrive in the genome-wide association studies industry. This genome-wide association studies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genome-wide association studies market includes revenues earned by entities through sequencing, data analysis, bioinformatics support, biomarker discovery, and consulting for genetic association studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.